Kala is focused on developing innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to enhance topical delivery into ocular tissues.
As demonstrated in animal studies, the ability of MPPs to rapidly penetrate through and uniformly distribute across mucus barriers has translated into enhanced ocular pharmacokinetics of MPP-based eye drops in multiple animal models.
Kala’s product candidate KPI-121 is a novel nanoparticle formulation of loteprednol etabonate utilizing Kala’s MPP technology to enhance penetration into target tissues of the eye. KPI-121 has been studied in multiple clinical trials, including a 0.25% formulation for the treatment dry eye disease and 1% and 0.25% formulations for the treatment of post-surgical ocular inflammation and pain.
Kala is also developing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program for potential topical treatment of wet age-related macular degeneration (AMD) and other and other retinal diseases.